At a glance
- Originator Kyowa Hakko
- Developer Peter MacCallum Cancer Centre
- Class Cytostatic antibiotics
- Mechanism of Action Alkylating agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Oct 2006 Discontinued - Preclinical for Cancer in Australia (unspecified route)
- 13 Oct 2006 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 17 Apr 1997 No-Development-Reported for Cancer in Australia (Unknown route)